Spots Global Cancer Trial Database for Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
Official Title: A Phase II Study of Radiation With Concomitant and Then Sequential Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Who Have Undergone Surgery With Gliadel Wafer Insertion
Study ID: NCT00283543
Study Description
Brief Summary: To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and radiation with Temozolomide
Detailed Description: A phase II study of radiation with concomitant and then sequential Temozolomide in patients with newly diagnosed supratentorial malignant glioma who have undergone surgery with Gliadel wafer insertion. To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and limited field radiation therapy with concomitant Temozolomide followed by Temozolomide alone in patients undergoing initial surgery for newly diagnosed unifocal moderate to high grade glioma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Kentuckiana Cancer Institute, Louisville, Kentucky, United States
Contact Details
Name: Renato V. LaRocca, MD
Affiliation: Kentuckiana Cancer Institute
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
